Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...
The study found that the majority of people on Wegovy lost weight, on average 10% of their body weight, in the first 15 ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Novo Nordisk A/S (NYSE:NVO) está presenciando un aumento en el número de pacientes que comienzan a tomar su medicamento para la pérdida de peso, Wegovy, en Estados Unidos. Este aumento se produce a ...